Evidence map›Paper›PMID 33808253›Full record

ReviewMarine drugs2021

Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease.

Muhammad Bilal, Leonardo Vieira Nunes, Marco Thúlio Saviatto Duarte, Luiz Fernando Romanholo Ferreira, Renato Nery Soriano, Hafiz M N Iqbal

Abstract readReview
In one paragraph

Review in Marine drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Muhammad BilalSchool of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian 223003, China.ORCID 0000-0001-5388-3183
Leonardo Vieira NunesDepartment of Medicine, Federal University of Juiz de Fora, Juiz de Fora-MG 36036-900, Brazil.ORCID 0000-0003-3889-8613
Marco Thúlio Saviatto DuarteDepartment of Medicine, Federal University of Juiz de Fora, Governador Valadares-MG 35010-180, Brazil.ORCID 0000-0003-4602-0229
Luiz Fernando Romanholo FerreiraGraduate Program in Process Engineering, Tiradentes University (UNIT), Av. Murilo Dantas, 300, Farolândia, Aracaju-Sergipe 49032-490, Brazil.ORCID 0000-0002-5438-7795
Renato Nery SorianoDivision of Physiology and Biophysics, Department of Basic Life Sciences, Federal University of Juiz de Fora, Governador Valadares-MG 35010-180, Brazil.ORCID 0000-0002-3295-8120
Hafiz M N IqbalSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico.ORCID 0000-0003-4855-2720

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Naturally occurring biological entities with extractable and tunable structural and functional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical advancement, traditional medicinal practices to address and manage inflammatory bowel disease (IBD) are inefficient and the effect of the administered therapeutic cues is limited. The reasonable immune response or invasion should also be circumvented for successful clinical translation of engineered cues as highly efficient and robust bioactive entities. In this context, research is underway worldwide, and researchers have redirected or regained their interests in valorizing the naturally occurring biological entities/resources, for example, algal biome so-called "treasure of untouched or underexploited sources". Algal biome from the marine environment is an immense source of excellence that has also been demonstrated as a source of bioactive compounds with unique chemical, structural, and functional features. Moreover, the molecular modeling and synthesis of new drugs based on marine-derived therapeutic and biological cues can show greater efficacy and specificity for the therapeutics. Herein, an effort has been made to cover the existing literature gap on the exploitation of naturally occurring biological entities/resources to address and efficiently manage IBD. Following a brief background study, a focus was given to design characteristics, performance evaluation of engineered cues, and point-of-care IBD therapeutics of diverse bioactive compounds from the algal biome. Noteworthy potentialities of marine-derived biologically active compounds have also been spotlighted to underlying the impact role of bio-active elements with the related pathways. The current review is also focused on the applied standpoint and clinical translation of marine-derived bioactive compounds. Furthermore, a detailed overview of clinical applications and future perspectives are also given in this review.

Indexed as

AnimalsAnti-Inflammatory AgentsAquatic OrganismsHumansInflammation MediatorsInflammatory Bowel DiseasesIntestinesSignal TransductionAnti-Inflammatory AgentsInflammation Mediatorsalgal biomebioactive entitiesengineered cuesinflammatory bowel diseasepolysaccharidestherapeutic attributes

Identifiers

PMID33808253
PMCPMC8067156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.